@prefix : <http://model.geneontology.org/-1157495675#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@base <http://model.geneontology.org/-1157495675> .

<http://model.geneontology.org/-1157495675> rdf:type owl:Ontology .

#################################################################
#    Annotation properties
#################################################################

###  http://geneontology.org/lego/evidence
<http://geneontology.org/lego/evidence> rdf:type owl:AnnotationProperty .


###  http://geneontology.org/lego/modelstate
<http://geneontology.org/lego/modelstate> rdf:type owl:AnnotationProperty .


###  http://geneontology.org/lego/hint/layout/x
<http://geneontology.org/lego/hint/layout/x> rdf:type owl:AnnotationProperty .


###  http://geneontology.org/lego/hint/layout/y
<http://geneontology.org/lego/hint/layout/y> rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/contributor
<http://purl.org/dc/elements/1.1/contributor> rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/date
<http://purl.org/dc/elements/1.1/date> rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/source
<http://purl.org/dc/elements/1.1/source> rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/elements/1.1/title
<http://purl.org/dc/elements/1.1/title> rdf:type owl:AnnotationProperty .


###  http://purl.org/pav/providedBy
<http://purl.org/pav/providedBy> rdf:type owl:AnnotationProperty .


#################################################################
#    Object Properties
#################################################################

###  http://purl.obolibrary.org/obo/BFO_0000050
<http://purl.obolibrary.org/obo/BFO_0000050> rdf:type owl:ObjectProperty ;
                                             rdfs:label "part of" .


###  http://purl.obolibrary.org/obo/BFO_0000051
<http://purl.obolibrary.org/obo/BFO_0000051> rdf:type owl:ObjectProperty ;
                                             rdfs:label "has part" .


#################################################################
#    Classes
#################################################################

###  http://purl.obolibrary.org/obo/BFO_0000002
<http://purl.obolibrary.org/obo/BFO_0000002> rdf:type owl:Class ;
                                             rdfs:label "Continuant" .


###  http://purl.obolibrary.org/obo/ECO_0000313
<http://purl.obolibrary.org/obo/ECO_0000313> rdf:type owl:Class .


###  http://purl.obolibrary.org/obo/GO_0032991
<http://purl.obolibrary.org/obo/GO_0032991> rdf:type owl:Class ;
                                            rdfs:subClassOf <http://purl.obolibrary.org/obo/BFO_0000002> ;
                                            rdfs:label "Macromolecular Complex" .


###  http://www.biopax.org/release/biopax-level3.owl#Pathway
<http://www.biopax.org/release/biopax-level3.owl#Pathway> rdf:type owl:Class ;
                                                          rdfs:label "Pathway" .


###  http://www.biopax.org/release/biopax-level3.owl#Protein
<http://www.biopax.org/release/biopax-level3.owl#Protein> rdf:type owl:Class ;
                                                          rdfs:subClassOf <http://purl.obolibrary.org/obo/BFO_0000002> ;
                                                          rdfs:label "Protein" .


#################################################################
#    Individuals
#################################################################

###  http://model.geneontology.org/-2144184142
<http://model.geneontology.org/-2144184142> rdf:type owl:NamedIndividual ,
                                                     <http://purl.obolibrary.org/obo/ECO_0000313> ;
                                            <http://purl.org/dc/elements/1.1/contributor> "https://reactome.org/content/detail/R-HSA-8863678" ;
                                            <http://purl.org/dc/elements/1.1/date> "2018-02-14" ;
                                            <http://purl.org/dc/elements/1.1/source> "PMID:26848654" ;
                                            <http://purl.org/pav/providedBy> "https://reactome.org" .


###  http://model.geneontology.org/601836282
<http://model.geneontology.org/601836282> rdf:type owl:NamedIndividual ,
                                                   <http://purl.obolibrary.org/obo/ECO_0000313> ;
                                          <http://purl.org/dc/elements/1.1/contributor> "https://reactome.org/content/detail/R-HSA-8863678" ;
                                          <http://purl.org/dc/elements/1.1/date> "2018-02-14" ;
                                          <http://purl.org/dc/elements/1.1/source> "PMID:26848654" ;
                                          <http://purl.org/pav/providedBy> "https://reactome.org" .


###  http://www.reactome.org/biopax/63/48887#Pathway1259
<http://www.reactome.org/biopax/63/48887#Pathway1259> rdf:type owl:NamedIndividual ,
                                                               <http://www.biopax.org/release/biopax-level3.owl#Pathway> ;
                                                      <http://geneontology.org/lego/hint/layout/x> 60 ;
                                                      <http://geneontology.org/lego/hint/layout/y> 770 ;
                                                      <http://purl.org/dc/elements/1.1/contributor> "https://reactome.org/content/detail/R-HSA-8863678" ;
                                                      <http://purl.org/dc/elements/1.1/date> "2018-02-14" ;
                                                      <http://purl.org/pav/providedBy> "https://reactome.org" ;
                                                      rdfs:comment "Biological processes are captured in Reactome by identifying the molecules (DNA, RNA, protein, small molecules) involved in them and describing the details of their interactions. From this molecular viewpoint, human disease pathways have three mechanistic causes: the inclusion of microbially-expressed proteins, altered functions of human proteins, or changed expression levels of otherwise functionally normal human proteins.<p>The first group encompasses the infectious diseases such as influenza, tuberculosis and HIV infection. The second group involves human proteins modified either by a mutation or by an abnormal post-translational event that produces an aberrant protein with a novel function. Examples include somatic mutations of EGFR and FGFR (epidermal and fibroblast growth factor receptor) genes, which encode constitutively active receptors that signal even in the absence of their ligands, or the somatic mutation of IDH1 (isocitrate dehydrogenase 1) that leads to an enzyme active on 2-oxoglutarate rather than isocitrate, or the abnormal protein aggregations of amyloidosis which lead to diseases such as Alzheimer's.<p>Infectious diseases are represented in Reactome as microbial-human protein interactions and the consequent events. The existence of variant proteins and their association with disease-specific biological processes is represented by inclusion of the modified protein in a new or variant reaction, an extension to the 'normal' pathway. Diseases which result from proteins performing their normal functions but at abnormal rates can also be captured, though less directly. Many mutant alleles encode proteins that retain their normal functions but have abnormal stabilities or catalytic efficiencies, leading to normal reactions that proceed to abnormal extents. The phenotypes of such diseases can be revealed when pathway annotations are combined with expression or rate data from other sources." ;
                                                      rdfs:label "Disease" .


###  http://www.reactome.org/biopax/63/48887#Pathway1704
<http://www.reactome.org/biopax/63/48887#Pathway1704> rdf:type owl:NamedIndividual ,
                                                               <http://www.biopax.org/release/biopax-level3.owl#Pathway> ;
                                                      <http://purl.obolibrary.org/obo/BFO_0000050> <http://www.reactome.org/biopax/63/48887#Pathway1259> ;
                                                      <http://purl.obolibrary.org/obo/BFO_0000051> <http://www.reactome.org/biopax/63/48887#Pathway1705> ;
                                                      <http://geneontology.org/lego/hint/layout/x> 60 ;
                                                      <http://geneontology.org/lego/hint/layout/y> 320 ;
                                                      <http://purl.org/dc/elements/1.1/contributor> "Authored: Orlic-Milacic, Marija, 2016-08-18" ,
                                                                                                    "Edited: Orlic-Milacic, Marija, 2016-08-19" ,
                                                                                                    "Reviewed: D'Eustachio, Peter, 2016-08-18" ,
                                                                                                    "https://reactome.org/content/detail/R-HSA-8863678" ;
                                                      <http://purl.org/dc/elements/1.1/date> "2018-02-14" ;
                                                      <http://purl.org/pav/providedBy> "https://reactome.org" ;
                                                      rdfs:comment "Neurodegenerative diseases manifest as the progressive dysfunction and loss of neurons, which is frequently accompanied by formation of misfolded protein deposits in the brain. Classification of neurodegenerative diseases is based on clinical symptoms, which depend on the anatomical region affected by neuronal dysfunction, the identity of misfolded proteins and cellular and subcellular pathology.<br>In AlzheimerÂ’s disease (AD), beta-amyloid protein (APP) deposits form in the extracellular space, where they can make plaques, while abnormally phosphorylated tau protein (MAPT) accumulates in neuronal cells.<br>Beside AD, neuronal and/or glial inclusions of hyperphosphorylated tau are also found in Pick disease (PiD), neurofibrillary tangle-dementia (NFT), primary age-related tauopathy (PART), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD) and globular glial tauopathies (GGT).<br>In prion disease, such as Creutzfeldt-Jakob disease, deposits of PrP protein are formed mostly in the extracellular and presynaptic space. PrP deposits in neuronal cell bodies are mainly confined to endosomes and lysosomes, which is attributed to neuronal uptake of pathological proteins and intercellular prion spreading.<br>In Parkinson disease (PD) and dementia with Lewy bodies (DLB), deposits of alpha-synuclein (SNCA) are formed in the cytoplasm of neuronal cell bodies and neurites. In multiple system atrophy (MSA), deposits of alpha-synuclein form in the cytoplasm of glial cells (Papp-Lantos bodies).<br>Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are characterized by ubiquitin-positive cytoplasmic inclusions of TAR DNA-binding protein 43 (TARDBP, commonly known as TDP-43), a protein that normally localizes to the nucleus. Pathological TDP-43 inclusions have been associated with the TDP-43 gene mutations, as well as mutations in several other genes, including C9orf72, GRN, VCP, SQSTM1, DCTN1 and OPTN. TDP-43 inclusions have also been reported in AD, DLB, hippocampal sclerosis (HS) and chronic traumatic encephalopathy.<br>FUS protein-positive inclusion bodies are found in familial ALS, caused by mutations in the FUS gene, as well as in a small subgroup of FTLD-related diseases. FUS-positive inclusions may be accompanied by FET protein-positive inclusions.<br>For a detailed review of molecular pathology of neurodegenerative diseases, please refer to Kovacs 2016.<br>Within this broad domain, the process by which APP-triggered deregulation of CDK5 (cyclin-dependent kinase 5) triggers multiple neurodegenerative pathways associated with Alzheimer's disease has been annotated." ;
                                                      rdfs:label "Neurodegenerative Diseases" .

[ rdf:type owl:Axiom ;
   owl:annotatedSource <http://www.reactome.org/biopax/63/48887#Pathway1704> ;
   owl:annotatedProperty <http://purl.obolibrary.org/obo/BFO_0000050> ;
   owl:annotatedTarget <http://www.reactome.org/biopax/63/48887#Pathway1259> ;
   <http://geneontology.org/lego/evidence> <http://model.geneontology.org/601836282> ;
   <http://purl.org/dc/elements/1.1/contributor> "https://reactome.org/content/detail/R-HSA-8863678" ;
   <http://purl.org/dc/elements/1.1/date> "2018-02-14" ;
   <http://purl.org/pav/providedBy> "https://reactome.org"
 ] .

[ rdf:type owl:Axiom ;
   owl:annotatedSource <http://www.reactome.org/biopax/63/48887#Pathway1704> ;
   owl:annotatedProperty <http://purl.obolibrary.org/obo/BFO_0000051> ;
   owl:annotatedTarget <http://www.reactome.org/biopax/63/48887#Pathway1705> ;
   <http://geneontology.org/lego/evidence> <http://model.geneontology.org/-2144184142> ;
   <http://purl.org/dc/elements/1.1/contributor> "https://reactome.org/content/detail/R-HSA-8863678" ;
   <http://purl.org/dc/elements/1.1/date> "2018-02-14" ;
   <http://purl.org/pav/providedBy> "https://reactome.org"
 ] .


###  http://www.reactome.org/biopax/63/48887#Pathway1705
<http://www.reactome.org/biopax/63/48887#Pathway1705> rdf:type owl:NamedIndividual ,
                                                               <http://www.biopax.org/release/biopax-level3.owl#Pathway> ;
                                                      <http://geneontology.org/lego/hint/layout/x> 60 ,
                                                                                                   710 ;
                                                      <http://geneontology.org/lego/hint/layout/y> 1220 ,
                                                                                                   320 ;
                                                      <http://purl.org/dc/elements/1.1/contributor> "Authored: Shah, Kavita, 2016-02-23" ,
                                                                                                    "Edited: Orlic-Milacic, Marija, 2016-05-10" ,
                                                                                                    "https://reactome.org/content/detail/R-HSA-8863678" ;
                                                      <http://purl.org/dc/elements/1.1/date> "2018-02-14" ;
                                                      <http://purl.org/pav/providedBy> "https://reactome.org" ;
                                                      rdfs:comment "Post-mitotic neurons do not have an active cell cycle. However, deregulation of Cyclin Dependent Kinase-5 (CDK5) activity in these neurons can aberrantly activate various components of cell cycle leading to neuronal death (Chang et al. 2012). Random activation of cell cycle proteins has been shown to play a key role in the pathogenesis of several neurodegenerative disorders (Yang et al. 2003, Lopes et al. 2009). CDK5 is not activated by the canonical cyclins, but binds to its own specific partners, CDK5R1 and CDK5R2 (aka p35 and p39, respectively) (Tsai et al. 1994, Tang et al. 1995). Expression of p35 is nearly ubiquitous, whereas p39 is largely expressed in the central nervous system. A variety of neurotoxic insults such as beta-amyloid (A-beta), ischemia, excitotoxicity and oxidative stress disrupt the intracellular calcium homeostasis in neurons, thereby leading to the activation of calpain, which cleaves p35 into p25 and p10 (Lee et al. 2000). p25 has a six-fold longer half-life compared to p35 and lacks the membrane anchoring signal, which results in its constitutive activation and mislocalization of the CDK5:p25 complex to the cytoplasm and the nucleus. There, CDK5:p25 is able to access and phosphorylate a variety of atypical targets, triggering a cascade of neurotoxic pathways that culminate in neuronal death. One such neurotoxic pathway involves CDK5-mediated random activation of cell cycle proteins which culminate in neuronal death. Exposure of primary cortical neurons to oligomeric beta-amyloid (1-42) hyper-activates CDK5 due to p25 formation, which in turn phosphorylates CDC25A, CDC25B and CDC25C. CDK5 phosphorylates CDC25A at S40, S116 and S261; CDC25B at S50, T69, S160, S321 and S470; and CDC25C at T48, T67, S122, T130, S168 and S214. CDK5-mediated phosphorylation of CDC25A, CDC25B and CDC25C not only increases their phosphatase activities but also facilitates their release from 14-3-3 inhibitory binding. CDC25A, CDC25B and CDC25C in turn activate CDK1, CDK2 and CDK4 kinases causing neuronal death. Consistent with this mechanism, higher CDC25A, CDC25B and CDC25C activities were observed in human Alzheimer's disease (AD) clinical samples, as compared to age-matched controls. Inhibition of CDC25 isoforms confers neuroprotection to beta-amyloid toxicity, which underscores the contribution of this pathway to AD pathogenesis" ;
                                                      rdfs:label "Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models" .


#################################################################
#    Annotations
#################################################################

<http://model.geneontology.org/-1157495675> <http://geneontology.org/lego/modelstate> "development" ;
                                            <http://purl.org/dc/elements/1.1/contributor> "https://reactome.org/content/detail/R-HSA-8863678" ;
                                            <http://purl.org/dc/elements/1.1/date> "2018-02-14" ;
                                            <http://purl.org/dc/elements/1.1/title> "Reactome:Neurodegenerative Diseases" .


<http://purl.obolibrary.org/obo/BFO_0000066> rdfs:label "occurs in" .


<http://purl.obolibrary.org/obo/GO_0003674> rdfs:label "Molecular Function" .


<http://purl.obolibrary.org/obo/GO_0008150> rdfs:label "Biological Process" .


<http://purl.obolibrary.org/obo/RO_0001025> rdfs:label "located in" .


<http://purl.obolibrary.org/obo/RO_0002233> rdfs:label "has input" .


<http://purl.obolibrary.org/obo/RO_0002234> rdfs:label "has output" .


<http://purl.obolibrary.org/obo/RO_0002327> rdfs:label "enables" .


<http://purl.obolibrary.org/obo/RO_0002333> rdfs:label "enabled by" .


<http://purl.obolibrary.org/obo/RO_0002334> rdfs:label "regulated by" .


<http://purl.obolibrary.org/obo/RO_0002406> rdfs:label "directly activates (process to process)" .


<http://purl.obolibrary.org/obo/RO_0002408> rdfs:label "directly inhibits (process to process)" .


<http://purl.obolibrary.org/obo/RO_0002413> rdfs:label "directly provides input for (process to process)" .


<http://www.biopax.org/release/biopax-level3.owl#Reaction> rdfs:label "Reaction" .


###  Generated by the OWL API (version 5.1.3) https://github.com/owlcs/owlapi/
